MX2009000650A - Vacunas para malaria. - Google Patents

Vacunas para malaria.

Info

Publication number
MX2009000650A
MX2009000650A MX2009000650A MX2009000650A MX2009000650A MX 2009000650 A MX2009000650 A MX 2009000650A MX 2009000650 A MX2009000650 A MX 2009000650A MX 2009000650 A MX2009000650 A MX 2009000650A MX 2009000650 A MX2009000650 A MX 2009000650A
Authority
MX
Mexico
Prior art keywords
protein
vivax
same
derived
vaccines
Prior art date
Application number
MX2009000650A
Other languages
English (en)
Inventor
Martine Marchand
Joseph D Cohen
Christian F Ockenhouse
Anjali Yadava
Original Assignee
Secretary Of The Army The Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Secretary Of The Army The Unit filed Critical Secretary Of The Army The Unit
Publication of MX2009000650A publication Critical patent/MX2009000650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una proteína novedosa híbrida / de fusión derivada de la proteína CS de Plasmodium vivax (P. vivax), los procedimientos para preparar y purificar la misma, su uso en medicina, particularmente en la prevención de infecciones de malaria, por ejemplo las provocadas por P. vivax, las composiciones/vacunas que contienen la proteína o anticuerpos contra la proteína tales como anticuerpos monoclonales o policlonales y uso de los mismos, particularmente en terapia. La invención también se extiende a partículas de lipoproteína de dicha proteína híbrida y formulaciones / vacunas que comprenden la misma y su uso. En particular se refiere a una proteína de fusión híbrida inmunogénica que comprende: a.menos una unidad de repetición derivada de la región de repetición de una proteína de circumsporozoito de tipo I de P. vivax, b. al menos una unidad de repetición derivada de la región de repetición de una proteína de circumsporozoito de tipo II de P. vivax., y antígeno S de superficie derivado del virus de Hepatitis B, o un fragmento del mismo.
MX2009000650A 2006-07-18 2007-07-16 Vacunas para malaria. MX2009000650A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines
PCT/EP2007/057301 WO2008009652A2 (en) 2006-07-18 2007-07-16 Vaccines for malaria

Publications (1)

Publication Number Publication Date
MX2009000650A true MX2009000650A (es) 2009-07-02

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009000650A MX2009000650A (es) 2006-07-18 2007-07-16 Vacunas para malaria.
MX2009000655A MX2009000655A (es) 2006-07-18 2007-07-16 Vacunasd para malaria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009000655A MX2009000655A (es) 2006-07-18 2007-07-16 Vacunasd para malaria.

Country Status (22)

Country Link
US (2) US9592282B2 (es)
EP (2) EP2040742B1 (es)
JP (2) JP5222289B2 (es)
KR (2) KR20090094213A (es)
AR (1) AR061894A1 (es)
AU (2) AU2007276219B2 (es)
BR (2) BRPI0715581A2 (es)
CA (2) CA2657353A1 (es)
CO (2) CO6150189A2 (es)
CR (2) CR10561A (es)
EA (2) EA200900033A1 (es)
ES (2) ES2525732T3 (es)
IL (2) IL196410A0 (es)
MA (2) MA30671B1 (es)
MX (2) MX2009000650A (es)
NO (2) NO20090177L (es)
NZ (2) NZ574238A (es)
PE (1) PE20080428A1 (es)
SG (2) SG173363A1 (es)
TW (1) TW200819462A (es)
WO (2) WO2008009650A2 (es)
ZA (1) ZA200900386B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
BRPI0715581A2 (pt) * 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
UY31510A1 (es) * 2007-12-06 2009-08-03 Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
TW200940087A (en) * 2007-12-24 2009-10-01 Glaxosmithkline Biolog Sa Vaccines for malaria
WO2010036293A1 (en) * 2008-09-24 2010-04-01 The Johns Hokins University Malaria vaccine
ES2532015T3 (es) * 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123412A1 (en) * 2012-02-17 2013-08-22 Children's Medical Center Corporation Conformation-stabilized trap antigens
WO2014111733A1 (en) * 2013-01-21 2014-07-24 Isis Innovation Limited Composition and uses thereof
EP3213638A1 (en) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Vegan cheese analogue
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
EP3559669A4 (en) * 2016-12-23 2020-11-18 The Walter and Eliza Hall Institute of Medical Research SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PLASMODIUM VIVAX
JP7305057B2 (ja) 2020-09-16 2023-07-07 三菱電機株式会社 前照灯装置

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE118784T1 (de) * 1985-07-12 1995-03-15 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DK0614465T3 (da) 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
DE69434221T2 (de) * 1993-09-10 2006-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bindungsdomänen von Plasmodius Vivax und Plasmodium Falciparum Erythrozyten bindenden Proteinen
DK0729473T3 (da) 1993-11-17 2000-10-30 Deutsche Om Arzneimittel Gmbh Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU1600401A (en) * 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
CA2451864C (en) 2001-06-22 2013-01-15 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
EP1636370B1 (en) 2003-06-20 2014-04-16 The Trustees of The University of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
JP4898434B2 (ja) 2003-06-20 2012-03-14 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
AU2006214694B2 (en) * 2005-01-18 2011-09-08 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
BRPI0715581A2 (pt) * 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
TW200940087A (en) * 2007-12-24 2009-10-01 Glaxosmithkline Biolog Sa Vaccines for malaria

Also Published As

Publication number Publication date
WO2008009652A2 (en) 2008-01-24
SG173363A1 (en) 2011-08-29
NZ574239A (en) 2011-12-22
BRPI0714326A2 (pt) 2013-05-07
MA30671B1 (fr) 2009-08-03
AR061894A1 (es) 2008-10-01
MX2009000655A (es) 2009-07-02
JP5222289B2 (ja) 2013-06-26
EP2040742A2 (en) 2009-04-01
NZ574238A (en) 2012-02-24
ES2437082T3 (es) 2014-01-08
JP5592110B2 (ja) 2014-09-17
EP2040743B1 (en) 2013-10-02
JP2009543569A (ja) 2009-12-10
AU2007276217B2 (en) 2013-08-29
PE20080428A1 (es) 2008-05-15
CO6150189A2 (es) 2010-04-20
JP2009543846A (ja) 2009-12-10
BRPI0715581A2 (pt) 2013-04-24
IL196410A0 (en) 2011-08-01
US9364525B2 (en) 2016-06-14
AU2007276217A1 (en) 2008-01-24
KR20090094213A (ko) 2009-09-04
CA2657353A1 (en) 2008-01-24
CA2657279A1 (en) 2008-01-24
SG173377A1 (en) 2011-08-29
EP2040742B1 (en) 2014-10-29
NO20090177L (no) 2009-02-16
ZA200900386B (en) 2014-03-26
AU2007276217A8 (en) 2009-02-26
WO2008009652A3 (en) 2008-05-08
TW200819462A (en) 2008-05-01
EA200900033A1 (ru) 2009-12-30
AU2007276219A1 (en) 2008-01-24
US9592282B2 (en) 2017-03-14
ES2525732T3 (es) 2014-12-29
MA30670B1 (fr) 2009-08-03
EA200900032A1 (ru) 2011-02-28
NO20090178L (no) 2009-02-09
WO2008009650A2 (en) 2008-01-24
WO2008009650A3 (en) 2008-04-10
CR10561A (es) 2009-04-29
IL196471A0 (en) 2011-08-01
CR10555A (es) 2009-04-29
US20100150998A1 (en) 2010-06-17
EP2040743A2 (en) 2009-04-01
US20100062028A1 (en) 2010-03-11
AU2007276219B2 (en) 2013-10-03
CO6150187A2 (es) 2010-04-20
KR20090092752A (ko) 2009-09-01

Similar Documents

Publication Publication Date Title
MX2009000650A (es) Vacunas para malaria.
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
DK1951296T3 (da) Celleafledte virale vacciner med lave niveauer af restcelle-DNA
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
ATE463515T1 (de) Chimaere rekombinante antigene von toxoplasma gondii
MX2010006984A (es) Vacunas contra la malaria.
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
WO2011007961A3 (en) Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
TNSN08184A1 (en) Chimeric antigens and vaccines
UY31574A1 (es) Vacunas contra la malaria
UA95293C2 (en) Vaccines for malaria
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
WO2005117956A3 (en) Neisserial vaccines
TH98092B (th) วัคซีนสำหรับมาลาเรีย
TH98092A (th) วัคซีนสำหรับมาลาเรีย
WO2008027414A3 (en) Novel p. falciparum vaccine proteins and coding sequences
MX358496B (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.
TH104139A (th) วัคซีนสำหรับมาลาเรีย

Legal Events

Date Code Title Description
FG Grant or registration